Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan
Phase 2
Completed
- Conditions
- Postoperative Supraventricular Tachyarrythmia
- Registration Number
- NCT00212680
- Lead Sponsor
- Ono Pharma USA Inc
- Brief Summary
The purpose of this study was to evaluate the dose-dependent effects of ONO-1101 on efficacy and safety in patients with postoperative supraventricular tachyarrhythmias.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- 20-80 years old
- Postoperative supraventricular tachyarrhythmias (sinus tachycardia, those with a heart rate of 120 beats/min or higher, and supraventricular arrhythmia, those with a heart rate of 100 beats/min or higher)
- Within 7 days postoperatively
- Other inclusion criteria as specified in the protocol
Exclusion Criteria
- Acute myocardial infarction (within 1 month after onset)
- Severe heart failure (New York Heart Association functional class III or higher)
- Atrioventricular block (grade II or higher),or sick sinus syndrome
- Other exclusion criteria as specified in the protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Percentage of patients achieving 20% reduction in heart rate at each dose
- Secondary Outcome Measures
Name Time Method Heart Rate, Blood pressure and 12-lead ECG
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does ONO-1101 utilize to manage postoperative supraventricular tachyarrhythmias?
How does ONO-1101 compare to standard antiarrhythmic drugs like amiodarone in treating postoperative tachyarrhythmias?
Are there specific biomarkers that correlate with ONO-1101 efficacy in postoperative cardiac patients?
What are the potential adverse events associated with ONO-1101 and how are they managed in clinical practice?
What other pharmaceutical compounds or combination therapies are being explored for postoperative supraventricular tachyarrhythmias alongside ONO-1101?